Aktienanalyse zu Forte Biosciences Inc (FBRX)FBRXForte Biosciences Inc

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Forte Biosciences Inc. (FBRX) is currently trading at $76.92, very close to the acquisition price of $77 per share. The stock has shown a remarkable year-to-date change of +225.79% and a one-year change of +579.81%, indicating strong performance. However, the RSI is at 83.126, suggesting it is overbought, and analysts have downgraded their ratings to Hold, indicating limited upside potential. Given these factors, it may be prudent to hold rather than buy at this price level, as the acquisition price caps potential gains.